SCHEMBL6411701

SCHEMBL6411701

CCC(=O)N[C@H]1CC[C@H](CCCN2CCC(Cc3cc(OC)ccc3Br)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 18/20 0.56
SLC6A4 P31645 18/20 0.56
GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411694 1.00 HTR1A (0.56) HTR1ASLC6A4GSK3B
SCHEMBL6415390 0.95 HTR1A (0.57) HTR1ASLC6A4
SCHEMBL6415388 0.95 HTR1A (0.57) HTR1ASLC6A4
SCHEMBL6411757 0.93 HTR1A (0.56) HTR1ASLC6A4
SCHEMBL6411759 0.93 HTR1A (0.56) HTR1ASLC6A4
SCHEMBL6412032 0.92 HTR1A (0.55) HTR1ASLC6A4
SCHEMBL6412030 0.92 HTR1A (0.55) HTR1ASLC6A4
SCHEMBL6416472 0.91 HTR1A (0.51) HTR1ASLC6A4
SCHEMBL6416470 0.91 HTR1A (0.51) HTR1ASLC6A4
SCHEMBL6420238 0.91 HTR1A (0.57) HTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065140-A1 Serotonine reuptake inhibitor SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2005-03-24 US disclosed
EP-1466901-A1 SEROTONINE REUPTAKE INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065140-A1 Serotonine reuptake inhibitor HTR1A, SLC6A4, SLC6A2 HTR1A 1/4885SLC6A4 2/4885GSK3B 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.